



Larry Hogan, Governor · Boyd K. Rutherford, Lt. Governor · Dennis R. Schrader, Acting Secretary

MARYLAND MEDICAL ASSISTANCE PROGRAM

Hospital Transmittal No. 278

MCO Transmittal No. 142

Pharmacy Transmittal No. 210

Physician Transmittal No. 148

December 17, 2020

TO: Hospitals
Managed Care Organizations (MCOs)
Pharmacies
Physicians
Neurologists

FROM: Alex Shekhdar, Acting Director
Medical Benefits Management

RE: Updated Preauthorization and Billing Instructions for Zolgensma®

Note: Please ensure that appropriate staff members in your organization are informed of the contents of this transmittal.

The purpose of this transmittal is to update the billing instructions for Zolgensma®. This guidance supersedes that provided in [Hospital Transmittal No. 272](#), [MCO Transmittal No. 136](#), [Pharmacy Transmittal No. 209](#), and [Physician Transmittal No. 417](#).

Effective January 1, 2021, the HealthChoice Managed Care Organizations (MCOs) will be responsible for the preauthorization, processing, and payment for Zolgensma® for HealthChoice participants. Fee-for-Service (FFS) claims will continue to be processed by the Maryland Department of Health (MDH). Providers should contact the HealthChoice participant's respective MCO for any preauthorization requirements related to Zolgensma®. Providers should follow the instructions outlined below when requesting FFS authorization and payment for Zolgensma® starting on January 1, 2021.

The Centers of Medicare and Medicaid Services (CMS) assigned a permanent J-code for this drug on July 1, 2020. MDH is now reimbursing providers for Zolgensma® using J3399. Providers are still required to report a valid 11-digit National Drug Code (NDC) number on the claim.

Fee-for-Service Preauthorization

Providers must obtain a preauthorization for Zolgensma® from MDH. Only one preauthorization will be issued by MDH per Medicaid participant. Preauthorizations may be requested from either the Professional Services Program or the Pharmacy Program. Once the service is rendered, the claim must be submitted through the Program in which the preauthorization was obtained. Requesting a preauthorization from more than one Program for the same participant is not permitted.

For preauthorization requests through the Professional Services Program, please refer to the following [clinical criteria](#) and [Preauthorization Request Form - Physician Administered Injectable Drugs](#).

For preauthorization requests when Zolgensma® is purchased and dispensed through a pharmacy, please refer to the following [clinical criteria](#) and [High Cost Drug Preauthorization form](#).

Updated Fee-for-Service Billing Instructions

In order for MDH to pay for Zolgensma®, the drug manufacturer must participate in the Medicaid Drug Rebate Program. Please make sure the J-Code/NDC is rebatable by going to the NDC Unit of Measure Listing on the [Maryland Medical Program's Web Services site](#).

Physicians

Zolgensma® will be reimbursed using the HCPCS code J3399 on the CMS-1500 claim form. Providers must report a valid 11-digit NDC number and the quantity administered. Please fax the CMS-1500 claim form to 410-767-6034 for processing. Electronic claims will NOT be accepted.

Pharmacies

Prescribers must complete the medication preauthorization process for Zolgensma®. Once the prior authorization has been issued, pharmacies may process the medication claim. MDH will reimburse the pharmacy for the medication if all criteria for coverage are met.

Questions

For questions related to obtaining a preauthorization through the Pharmacy Program, please call the Pharmacy Hotline at 1-800-492-5231, option 3.

For questions related to obtaining a preauthorization through the Professional Services Program, please email kim.stevenson@maryland.gov.

For MCO questions, please contact Pam Williams by email at pam.williams@maryland.gov.